Merus (MRUS – Research Report) received a Buy rating and price target from Truist Financial analyst Asthika Goonewardene today. The company’s shares opened today at $46.06.
According to TipRanks, Goonewardene is an analyst with an average return of -3.6% and a 32.31% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Genmab, Iovance Biotherapeutics, and Mersana Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merus with a $61.57 average price target.
Based on Merus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.03 million and a GAAP net loss of $23.01 million. In comparison, last year the company earned a revenue of $6.58 million and had a GAAP net loss of $24.62 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merus (MRUS) Company Description:
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
Read More on MRUS:
- Merus granted BTD by the FDA for petosemtamab
- Merus reports Q1 EPS (59c), consensus (81c)
- Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
- Merus NV Shareholders Endorse Governance and Incentive Plans
- FDA accepts priority review for Merus Zeno BLA for NRG1+ NSCLC, PDAC treatment
